Total: $4,684.02M | ||||
Company (Symbol)# (M) |
Type Of Financing |
Number Of Shares, Units Or Warrants |
Amount Raised (M) |
Investors; Placement Agents; Details (Date)@ |
| ||||
Acacia Research Corp. (ACTG) |
Private placement of common stock and warrants |
6.8U |
$5 |
Acacia raised $5M through the sale of 6.8M units representing Acacia Research-Combimatrix stock and warrants; participants included Amit Kumar, Tom Akin and John Abeles; each unit will consist of one share and a five-year warrant to purchase 1.5 shares at 55 cents per share (5/8) |
Acura Pharmaceuticals Inc. (OTC BB:ACUR) |
Bridge financing |
N/A |
$1.2 |
Acura completed the draw down of a $1.2M bridge financing committed by Essex Woodlands Health Ventures, Care Capital LLC and Galen Partners (5/21) |
Aeolus Pharmaceuticals Inc. (OTC BB:AOLS) |
Private placement of common stock |
2.7S and W for 2S |
$2 |
Aeolus raised $2M through the sale of stock and warrants; Rodman & Renshaw LLC served as the placement agent (5/23) |
Allon Therapeutics Inc. (Canada; TSX:NPC) |
Bought-deal financing |
12.5U |
C$15 ($13.6) |
Allon sold 12.5M units at C$1.20 per unit to a syndicate of Canadian securities dealers; each unit consists of one common share and half a warrant; the financing was led by Blackmont Capital Inc., and included GMP Securities LP, Cormark Securities Inc. and Versant Partners Inc. (5/9) |
Ambrilia Biopharma Inc. (Canada; TSX:AMB) |
Private placement of common stock |
2.3S |
$0.1 |
Ambrilia raised a total of $5.5M through a private placement begun in April; $5.4M of the amount was accounted for in last month's chart (5/21) |
AMDL Inc. (AMEX:ADL) |
Private placement of common stock and warrants |
2S and W for 1M |
$3.8 |
AMDL is raising $3.8M through the sale of 2M shares and warrants for 1M shares (5/7) |
Amgen Inc. (AMGN) |
Private placement of notes |
N/A |
$4,000 |
Amgen priced $4B in notes: $1.1B of 5.85% senior notes due 2017; $900M of 6.375% senior notes due 2037; and $2B of 18-month floating-rate senior notes (5/25) |
Anticus International Corp. (PK:ATCI) |
Private placement of units |
5.7U |
$0.4 |
Anticus raised $400,000 through a private placement of 5.7M units at 7 cents per unit; each unit consists of a common share, a one-year Class A warrant to purchase a common share at 12 cents and a two-year Class B piggy-back warrant to purchase a common share at 20 cents (5/30) |
Arrowhead Research Corp. (ARWR) |
Private placement of units |
2.8U |
$16.5 |
Arrowhead agreed to sell 2.8M units; investors are purchasing shares priced at $5.78 each and will receive warrants to buy another 712,362 shares at $7.06; Global Crown Capital LLC acted as exclusive placement agent (5/18) |
AspenBio Pharma Inc. (OTC BB:APNB) |
Warrant conversion |
W for 7.5S |
$9.3 |
AspenBio raised $9.3M, exchanging 7.5M shares for warrants issued as part of public offerings in 2004 and 2005 (5/8) |
Avalon Pharmaceuticals Inc. (AVRX) |
Private placement of stock and warrants |
3.84S and W for 0.96S |
$20 |
Avalon raised $20M selling 3.84M shares at $5.21 each; investors also got five-year warrants to buy up to 959,693 additional shares at $6 each (5/25) |
Bioenvision Inc. (BIVN) |
Warrant exercise |
W for 3S and W for 0.9S |
$7.4 |
Bioenvision raised $7.4M after existing investors exercised warrants to purchase 3M shares at $2 each, and SCO Capital and its affiliates exercised warrants to buy 938,333 shares at $1.50 each (5/7) |
BioSante Pharmaceuticals Inc. (AMEX:BPA) |
Private placement of common stock and warrants |
2.75S and W for 0.69S |
$16.5 |
BioSante entered into definitive agreements with institutional and other accredited investors on a placement of 2.75M shares at $6 each; investors also get warrants to buy 688,750 additional shares at $8 each; Rodman & Renshaw LLC is lead placement agent, with Oppenheimer & Co. Inc. (5/25) |
Boston Life Sciences Inc. (BLSI) |
Private placement of a convertible promissory note |
N/A |
$6 |
BLSI raised $6M issuing the note to an investment fund managed by Highbridge Capital Manage- ment LLC (5/3) |
CardioVascular BioTherapeutics Inc. (OTC BB:CVBT) |
Private placement of common stock |
15S |
$15 |
Company raised $15M in the sale of 15M shares at $1 each to Swiss investor FirmInvest AG (5/24) |
Ceapro Inc. (Canada; CDNX: CZO) |
Private placement of units |
N/A |
C$2 ($1.8) |
Ceapro raised $1.8M through a placement brokered by Northern Securities Inc.; it offered units for C$0.31, with each unit consisting of one common share and half a warrant (5/24) |
Cougar Biotechnology Inc. (OTC BB:CGRB) |
Private placement of common stock |
2.5S |
$50 |
Cougar raised $50M by selling 2.5M shares at $20 each; Leerink Swann & Co. served as sole place- ment agent (5/3) |
Discovery Laboratories Inc. (DSCO) |
Credit facility |
N/A |
$12.5 |
Discovery secured the facility with Merrill Lynch Capital (5/23) |
Immunomedics Inc. (IMMU) |
Direct offering |
4.8S |
$24 |
Immunomedics raised $24M in the direct offering of 4.8M shares at $4.95 per share; Lazard Capital Markets LLC acted as the exclusive placement agent for the offering (5/2) |
Inovio Biomedical Corp. (AMEX:INO) |
Direct offering |
4.6S |
$16.2 |
Inovio raised $16.2M offering 4.6M shares at $3.52 per share to institutional and accredited investors (5/16) |
Insmed Inc. (INSM) |
Private placement of common stock and warrants |
W for 2S |
$18.2 |
Insmed is raising $18.2M through the sale of 20M shares and five-year warrants to buy about 2M more shares at $1.10 each (5/4) |
IntelGenx Technologies Corp. (OTC BB:IGXT) |
Secured convertible debenture sale |
N/A |
$1.5 |
IntelGenx raised $1.5M through the sale (5/24) |
Intercytex Group plc (UK; LSE:ICX) |
Private placement of common stock |
21.1S |
£12 ($23.9) |
Intercytex raised $23.9M in the placement of 21.1M shares at L0.52 each (5/9)** |
IsoTis Inc. (ISOT) |
Credit facility |
N/A |
$20 |
The facility consists of a $10M loan and a $10M revolving line of credit from Merrill Lynch Capital and Silicon Valley Bank (5/30) |
Karo Bio AB (Sweden; SSE:KARO) |
Rights offering |
38.7S |
SEK406 ($59.6) |
Karo Bio raised $59.6M in the discounted rights offering (5/16)** |
Lorus Therapeutics Inc. (Canada; AMEX:LRP; TSX:LOR) |
Private placement of common stock |
ND |
$7.8 |
Lorus raised the money through a recapitalization plan with investor 6707157 Canada Inc.; the in- vestor will acquire 41% of voting common shares and all nonvoting common shares (5/2) |
MediCult A/S (Denmark; OSLO:MEC) |
Rights offering |
ND |
NOK82.5 ($13.7) |
MediCult raised $13.7M in a rights offering fully underwritten by Orkla Invest (5/2)** |
Modigene Inc. (OTC BB: MODG) |
Private placement of common stock and warrants |
6.4S and 1.6W |
$15 |
Modigene issued about 6.4M shares at $1.50 each and about 1.6M warrants that expire in five years and have an exercise price of $2.50; Phillip Frost and several other investors contributed another $2M; in a final closing, company officials pro- vided another $3.37M (5/15) |
Neurochem Inc. (Canada; NRMX) |
Private placement of convertible notes |
ND |
$80 |
Neurochem privately placed $80M in convertible notes, which consisted of $40M of 6% senior convertible notes due 2027 and $40M of 5% senior subordinated convertible notes due 2012; the company will issue warrants to purchase 2.3M shares at $12.68 each (5/2) |
NitroMed Inc. (NTMD) |
Registered direct offering |
7.6S |
$18.3 |
NitroMed raised $18.3M through the sale of 7.6M shares at $2.60 each; Thomas Weisel Partners LLC acted as the sole placement agent (5/24) |
PharmaGap Inc. (Canada; CDNX:GAP) |
Private placement of units and preferred shares |
2U and 2.4S |
C$0.55 ($0.5) |
PharmaGap raised $500,000 through an invest- ment from Dundee Securities Corp., which acquired 2M common equity units and 2.4M Series I preferred shares, and now owns 9.4% of the common shares outstanding (5/7) |
Pluristem Life Systems Inc. (OTC BB:PLRS) |
Private placement |
ND |
$13.5 |
Pluristem raised $13.5M through a private investment (5/22) |
Progen Pharmaceuticals Ltd. (Australia; PGLA) |
Private placement of common stock |
6.9S |
$61 |
Progen raised about $61M through U.S. institution- al and other investors; Thomas Weisel Partners LLC was the sole placement agent; the amount raised includes an entitlements offer to existing stockholders; Bell Potter and eG Capital is the underwriter (5/3) |
Quest Group International Inc. (OTC BB:QSTG) |
Private placement of common stock |
ND |
$20 |
Quest raised $20M in the financing; Hunter World Markets Inc. acted as its sole placement agent (5/18) |
Quest PharmaTech Inc. (Canada; CDNX:QPT) |
Private placement of common stock |
6.67S |
C$1 ($0.94) |
Quest raised $940,000 through a placement of 6.67M shares at C$0.15 per share (5/31) |
RXi Pharmaceuticals Corp. (subsidiary of CytRx Corp.; CYTR) |
Private placement |
ND |
$15 |
CytRx contributed $15M to its subsidiary, increas- ing its ownership in RXi to nearly 90% (5/1) |
Sernova Corp. (Canada; CDNX:SVA) |
Warrant exercise |
4W |
$2.4 |
Sernova raised $2.4M through the exercise of 4M outstanding warrants; they were exercised at 60 cents per share (5/10) |
Sinobiomed Inc. (OTC BB: SOBM) |
Private placement of units |
9.29U |
$9.68 |
Sinobiomed raised the money through two private placements; each unit consisted of one common share and half a warrant; each whole warrant en- titles the holder to purchase one additional share for two years (5/31) |
Spectrum Pharmaceuticals Inc. (SPPI) |
Private placement of common stock |
5.1S |
$32 |
Spectrum raised $32M in a registered direct offering; Oppenheimer & Co. acted as the lead placement agent, with Lazard Capital Markets as co-lead; co-placement agents were ThinkEquity Partners LLC and Rodman & Renshaw LLC (5/7) |
ThromboGenics NV (Belgium; BR:THR) |
Private placement of common stock |
2.21S |
€23.9 ($32.4) |
ThromboGenics raised $32.4M through the placement; KBC Securities acted as lead manager and was assisted by Kempen & Co. (5/9) |
Vasogen Inc. (VSGN) |
Private placement of common stock |
4.9S |
$16 |
Vasogen raised $16M offering 4.9M shares at $3.25 each to institutional investors; Rodman & Renshaw LLC and JMP Securities LLC are the placement agents (5/18) |
Viropro Inc. (OTC BB:VPRO) |
Debenture financing |
N/A |
C$1.4 ($1.3) |
Viropro closed a $1.3M debenture opened in March 2006 and payable in five tranches over the past year (5/24) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange | ||||
@ Refers to the date of the press release. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; BR = Brussels Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK= Pink Sheets; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange. |